Keyword: Johnson & Johnson
Johnson & Johnson is joining the growing ranks of biopharmas in working on a new vaccine for the coronavirus out of China.
Our final roundup of biotech news for the year and the decade.
As a part of its new digital orthopedic surgery platform, Johnson & Johnson’s DePuy Synthes division will work with Zebra Medical Vision.
J&J is moving to fully take over its robotic surgery venture with Google’s sibling company, Verily, by acquiring the remaining stake of Verb Surgical.
Johnson & Johnson’s Balversa is the first targeted therapy approved by the FDA to treat bladder cancer.
Both doses of GlaxoSmithKline’s BCMA-targeting antibody-drug conjugate shrank tumors in about one-third of patients with advanced multiple myeloma.
Pyxis brings on SpringWorks founder Sullivan; Insitro hires chief data officer Batzoglou; Frinzi to step down from J&J Vision.
Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.
Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.
UCB’s dual inhibitor recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.